Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00024076|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : August 3, 2020
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer Malignant Mesothelioma Metastatic Cancer Thymoma and Thymic Carcinoma||Procedure: radiofrequency ablation||Phase 2|
- Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
- Determine the efficacy of this treatment, in terms of local control, in these patients.
- Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.
OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.
Patients are followed at 1, 3, 6, and 12 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Radiofrequency Ablation of Pulmonary Malignancy|
|Study Start Date :||May 2000|
|Actual Primary Completion Date :||December 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00024076
|United States, California|
|Jonsson Comprehensive Cancer Center, UCLA|
|Los Angeles, California, United States, 90095-1781|
|Study Chair:||Robert D. Suh, MD||Jonsson Comprehensive Cancer Center|